Quantification of 11C-PIB kinetics in cardiac amyloidosis

Kero, Tanja; Sörensen, Jens; Antoni, Gunnar; Wilking, Helena; Carlson, Kristina; Vedin, Ola; Rosengren, Sara; Wikström, Gerhard; Lubberink, Mark

doi:10.1007/s12350-018-1349-x

Cited by 13 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 . The most common were cardiac biopsy [ 6 , 10 , 24 – 26 , 28 , 31 – 39 , 41 , 43 , 44 , 46 , 47 , 49 – 54 ], DNA genotyping [ 6 , 10 , 25 , 27 – 30 , 33 , 37 , 40 – 45 , 47 , 48 , 51 – 53 , 55 – 58 ], and extracardiac biopsy, performed in 26 (68%), 24 (63%), and 19 (50%) studies, respectively. Biopsy was not performed in 6 (16%) studies [ 27 , 29 , 30 , 40 , 55 , 57 ], but DNA genotyping was conducted in all 6 of these studies and nuclear scintigraphy in 2 of the 6 studies.…”

Section: Resultsmentioning

confidence: 99%

Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges

et al. 2020

View full text Add to dashboard Cite

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, life-threatening disease characterized by deposition of insoluble amyloid fibrils in the myocardium, resulting in cardiac structural and functional abnormalities and ultimately heart failure. Disease frequency is reportedly lower in women than men, but sex-related differences have not been well established. We conducted a systematic literature review (SLR), based on PRISMA-P guidelines and registered with PROSPERO, to assess whether the epidemiology and clinical presentation of ATTR-CM differ between women and men. MEDLINE, Embase, and Cochrane databases and selected conference proceedings were searched (August 16, 2019) to identify observational and clinical studies reporting sex-specific data for patients with wild-type or hereditary ATTR-CM. Of 193 publications satisfying final eligibility criteria, 69 studies were included in our pooled analysis. Among the 4669 patients with ATTR-CM analyzed, 791 (17%) were women, including 174 (9%), 366 (29%), and 251 (18%) in studies of wild-type, hereditary, and undefined ATTR-CM, respectively. Data available on disease characteristics were limited and very heterogeneous, but trends suggested some cardiac structural/functional differences, i.e., lower interventricular septal and posterior wall thickness and left ventricular (LV) end diastolic diameter, and higher LV ejection fractions, in women versus men across ATTR-CM subtypes. Because LV wall thickness > 12 mm is generally the suggested threshold for ATTR-CM diagnosis in both sexes, smaller cardiac anatomy in women with the disease may lead to underdiagnosis. Additional research and studies are needed to elucidate potential disparities between sexes in ATTR-CM frequency, clinical characteristics, and underlying biological mechanisms. This study was registered within the International Prospective Register of Systematic Reviews (PROSPERO) database of the University of York (CRD42019146995).

show abstract

Section: Resultsmentioning

confidence: 99%

Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges

et al. 2020

View full text Add to dashboard Cite

show abstract

“…RI was calculated using a simplified method inspired by Kero et al [31]. The RI was calculated as the SUV-value at 30 min divided by the area under the tissue curve integrated between 0 and 30 min for the same VOI.…”

Section: Discussionmentioning

confidence: 99%

Quantification of cardiac amyloid with [¹⁸F]Flutemetamol in patients with V30M hereditary transthyretin amyloidosis

Möckelind

Axelsson

Pilebro

et al. 2020

Amyloid

View full text Add to dashboard Cite

Background: Hereditary transthyretin amyloid (ATTRv) is a systemic amyloidosis with mainly neurological and cardiac symptoms. The aim of this study was to evaluate the outcome of [ 18 F]Flutemetamol PET/CT-scan of the heart in long-term survivors with ATTRV30M amyloidosis. Methods: Twenty-one patients with ATTRV30M amyloidosis and predominantly neurological symptoms, mainly negative on cardiac 99m technetium-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD)scintigraphy, were examined with a dynamic [ 18 F]Flutemetamol PET/CT-scan. Five patients suffering from Alzheimer's disease and one healthy individual served as controls. Volumes of interests were drawn over the intraventricular septum, lateral wall of the left ventricle and free wall of the right ventricle. Clinical records were reviewed for data from previous completed DPD-scintigraphy of the heart and echocardiography. Results: Patients with ATTRv amyloidosis had a higher cardiac uptake than the control-group in all analysed regions of the heart and could be identified with high accuracy (sensitivity 88%, specificity 100%) in static image acquisition at 30 or 60 min. We found no correlation between cardiac [ 18 F]Flutemetamol uptake and clinical variables. Conclusion: In this small study of selected patients, cardiac [ 18 F]Flutemetamol PET/CT could differentiate between healthy individuals and patients with ATTRV30M. [ 18 F]Flutemetamol PET/CT imaging of amyloidosis in patients with a negative DPD-scintigraphy has a potential as a diagnostic method.

show abstract

“…The ratio is also known as Standardized Uptake Value (SUV) [28]. Retention index (RI), calculated to assess the retention of radiotracers in myocardium over certain time interval, can be another important method measuring amyloid deposition quantitatively in PET imaging [29][30][31].…”

Section: Imaging Techniques and Radiotracersmentioning

confidence: 99%

Nuclear Imaging for the Diagnosis of Cardiac Amyloidosis in 2021

Uppal

Wang

et al. 2021

Diagnostics

View full text Add to dashboard Cite

Cardiac amyloidosis is caused by the deposition of misfolded protein fibrils into the extracellular space of the heart. The diagnosis of cardiac amyloidosis remains challenging because of the heterogeneous manifestations of the disease. There are many different types of amyloidosis with light-chain (AL) amyloidosis and transthyretin (ATTR) amyloidosis being the most common types of cardiac amyloidosis. Endomyocardial biopsy is considered the gold standard for diagnosing cardiac amyloidosis and differentiating amyloid subtypes, but its use is limited because of the invasive nature of the procedure, with risks for complications and the need for specialized training and centers to perform the procedure. Radionuclide cardiac imaging has recently become the most commonly performed test for the diagnosis of ATTR amyloidosis but is of limited value for the diagnosis of AL amyloidosis. Positron emission tomography has been increasingly used for the diagnosis of cardiac amyloidosis and its applications are expected to expand in the future. Imaging protocols are under refinement to achieve better quantification of the disease burden and prediction of prognosis.

show abstract

Quantification of 11C-PIB kinetics in cardiac amyloidosis

Abstract: An irreversible two-tissue model best describes the C-PIB uptake in cardiac amyloidosis. RI and SUV correlate well with K from the 2Tirr model. RI and SUV discriminate better between amyloidosis patients and controls than K based on population-average metabolite correction.

Cited by 13 publications

References 19 publications

Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges

Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges

Quantification of cardiac amyloid with [¹⁸F]Flutemetamol in patients with V30M hereditary transthyretin amyloidosis

Nuclear Imaging for the Diagnosis of Cardiac Amyloidosis in 2021

Contact Info

Product

Resources

About

Quantification of 11C-PIB kinetics in cardiac amyloidosis

Abstract: An irreversible two-tissue model best describes the C-PIB uptake in cardiac amyloidosis. RI and SUV correlate well with K from the 2Tirr model. RI and SUV discriminate better between amyloidosis patients and controls than K based on population-average metabolite correction.

Cited by 13 publications

References 19 publications

Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges

Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges

Quantification of cardiac amyloid with [18F]Flutemetamol in patients with V30M hereditary transthyretin amyloidosis

Nuclear Imaging for the Diagnosis of Cardiac Amyloidosis in 2021

Contact Info

Product

Resources

About

Quantification of cardiac amyloid with [¹⁸F]Flutemetamol in patients with V30M hereditary transthyretin amyloidosis